Seaport Therapeutics Q3 net loss widens 17% to $26.39 million
SPTX•Seaport Therapeutics’ third-quarter 2026 net loss widened 17% year over year to $26.39 million. It reported $403.8 million in cash, cash equivalents and investments at September 30, with funding expected to support operations into 2029.
1. Quarterly results
Research and development expenses rose 17% year over year to $23.89 million, primarily due to higher clinical development spending for GlyphAllo’s BUOY-1 trial. The company said enrollment remains on track in the Phase 2b depression trial, with topline data expected in the first half of 2027.
2. Trial plans
Seaport plans to start a potentially registration-enabling GlyphAgo Phase 2/3 anxiety trial in the first half of 2027, with results expected by year-end 2028.
